Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: A report from the Japanese Study Group for Pediatric Liver Tumor - PubMed (original) (raw)
Clinical Trial
doi: 10.1053/jpsu.2002.32886.
T Matsunaga, M Iwafuchi, Y Hayashi, H Ohkawa, M Ohira, T Okamatsu, T Sugito, Y Tsuchida, A Toyosaka, N Nagahara, H Nishihira, Y Hata, J Uchino, K Misugi, N Ohnuma; (Japanese Study Group for Pediatric Liver Tumor)
Affiliations
- PMID: 12037748
- DOI: 10.1053/jpsu.2002.32886
Clinical Trial
Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: A report from the Japanese Study Group for Pediatric Liver Tumor
F Sasaki et al. J Pediatr Surg. 2002 Jun.
Abstract
Purpose: Hepatoblastoma is the most common malignant liver tumor in childhood. Multicenter studies elucidate the optimal pre- or postoperative chemotherapeutic regimens. This report reviews the results of the Japanese Study Group for Pediatric Liver Tumor Protocol-1 (JPLT-1) and compares its outcomes with published reports of other studies.
Methods: From March 1991 to December 1999, 154 patients with malignant liver tumor including 145 cases of hepatoblastomas were enrolled in the JPLT study. Data from 134 cases were analyzed in this study. JPLT-1 protocol 91A was used for patients with stage I or II hepatoblastoma. The chemotherapy regimen consisted of repeated courses of cisplatin (CDDP), 40 mg/m(2), and tetrahydropyranyl (THP)-Adriamycin, 30 mg/m(2). JPLT-1 protocol 91B was administered to patients with stage IIIA, IIIB, or IV hepatoblastoma. The chemotherapy regimen consisted of repeated courses of CDDP, 80 mg/m(2), and THP-Adriamycin, 30 mg/m(2)/day for 2 days. Courses were repeated every 4 weeks as tolerated.
Results: Seven patients died of chemotherapy-related side effects. Six of them died of sepsis caused by leukopenia and 1 case of liver failure. Overall survival rate (3-year/6-year) was 100%/100% for stage I (n = 9), 100%/95.7% for stage II (n = 32), 76.6%/73.8% for stage IIIA (n = 48), 50.3%/50.3% for stage IIIB (n = 25), 64.8%/38.9% for stage IV (n = 20), and 77.8%/73.4% overall. For stage IIIA and B disease, intravenous chemotherapy was better than intraarterial chemotherapy (66.4% v 38.1% for event-free survival and 69.3% v. 57.1% for overall survival). Patients less than 1 year of age had a better prognosis than older patients, but age was not a significant prognostic factor by multivariate analysis.
Conclusions: The overall and event-free survival rates of the JPLT-1 study of hepatoblastoma were comparable with the results of other multicenter studies in Europe and the United States. The event-free survival rate at 3 years for stage IIIB and IV disease was under 50%. New treatment strategies are needed for patients with advanced hepatoblastoma.
Copyright 2002, Elsevier Science (USA). All rights reserved.
Similar articles
- Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT.
Hishiki T, Matsunaga T, Sasaki F, Yano M, Ida K, Horie H, Kondo S, Watanabe K, Oue T, Tajiri T, Kamimatsuse A, Ohnuma N, Hiyama E. Hishiki T, et al. Pediatr Surg Int. 2011 Jan;27(1):1-8. doi: 10.1007/s00383-010-2708-0. Pediatr Surg Int. 2011. PMID: 20922397 - [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B, Bode U, von Schweinitz D. Häberle B, et al. Klin Padiatr. 2003 May-Jun;215(3):159-65. doi: 10.1055/s-2003-39375. Klin Padiatr. 2003. PMID: 12778356 Clinical Trial. German. - Improved survival outcome for hepatoblastoma based on an optimal chemotherapeutic regimen--a report from the study group for pediatric solid malignant tumors in the Kyushu area.
Suita S, Tajiri T, Takamatsu H, Mizote H, Nagasaki A, Inomata Y, Hara T, Okamura J, Miyazaki S, Kawakami K, Eguchi H, Tsuneyoshi M; Committee for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan. Suita S, et al. J Pediatr Surg. 2004 Feb;39(2):195-8; discussion 195-8. doi: 10.1016/j.jpedsurg.2003.10.012. J Pediatr Surg. 2004. PMID: 14966739 Review. - Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group.
Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, Haas JE, King DR, Liu-Mares W, Sensel MG, Krailo MD. Ortega JA, et al. J Clin Oncol. 2000 Jul;18(14):2665-75. doi: 10.1200/JCO.2000.18.14.2665. J Clin Oncol. 2000. PMID: 10894865 Clinical Trial. - [Strategy for the treatment of hepatoblastoma in children].
Sasaki F. Sasaki F. Nihon Geka Gakkai Zasshi. 2005 Jul;106(7):427-30. Nihon Geka Gakkai Zasshi. 2005. PMID: 16045186 Review. Japanese.
Cited by
- Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration.
Meyers RL, Maibach R, Hiyama E, Häberle B, Krailo M, Rangaswami A, Aronson DC, Malogolowkin MH, Perilongo G, von Schweinitz D, Ansari M, Lopez-Terrada D, Tanaka Y, Alaggio R, Leuschner I, Hishiki T, Schmid I, Watanabe K, Yoshimura K, Feng Y, Rinaldi E, Saraceno D, Derosa M, Czauderna P. Meyers RL, et al. Lancet Oncol. 2017 Jan;18(1):122-131. doi: 10.1016/S1470-2045(16)30598-8. Epub 2016 Nov 22. Lancet Oncol. 2017. PMID: 27884679 Free PMC article. Clinical Trial. - Surgical Resection for Hepatoblastoma-Updated Survival Outcomes.
Sunil BJ, Palaniappan R, Venkitaraman B, Ranganathan R. Sunil BJ, et al. J Gastrointest Cancer. 2018 Dec;49(4):493-496. doi: 10.1007/s12029-017-0005-z. J Gastrointest Cancer. 2018. PMID: 28963691 - The clinical course in pediatric solid tumor patients with focal nodular hyperplasia of the liver.
Sugito K, Uekusa S, Kawashima H, Furuya T, Ohashi K, Inoue M, Ikeda T, Koshinaga T, Tomita R, Mugishima H, Maebayashi T. Sugito K, et al. Int J Clin Oncol. 2011 Oct;16(5):482-7. doi: 10.1007/s10147-011-0210-x. Epub 2011 Apr 1. Int J Clin Oncol. 2011. PMID: 21455626 - Adult hepatoblastoma successfully treated with multimodal treatment.
Nakamura S, Sho M, Kanehiro H, Tanaka T, Kichikawa K, Nakajima Y. Nakamura S, et al. Langenbecks Arch Surg. 2010 Nov;395(8):1165-8. doi: 10.1007/s00423-010-0630-5. Epub 2010 Apr 11. Langenbecks Arch Surg. 2010. PMID: 20383775 - [Current status of diagnosis and treatment of hepatoblastoma].
García-Miguel P, López Santamaría M. García-Miguel P, et al. Clin Transl Oncol. 2005 Aug;7(7):328-34. doi: 10.1007/BF02710274. Clin Transl Oncol. 2005. PMID: 16185597 Review. Spanish. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical